Advances in Linking Technologies Re-Instills Hope in ADC
According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", significant advancements in linking technologies have fuelled interest in ADCs. These advancements have paved the development of drugs such as ADCETRIS and Kadcyla. The industry is developing more precise and optimal positioning of the link between the cytotoxin and the antibody, resulting in a "homogeneous" product that may assure more efficient delivery of cytotoxin to the tumor cell, resulting in better efficacy and less...
View full press release